MLXIPL抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using MLXIPL mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.    

  
  

The MLXIPL antibody is designed to detect MLXIPL (MLX interacting protein-like), also known as carbohydrate response element-binding protein (ChREBP), a key transcriptional regulator in glucose and lipid metabolism. MLXIPL is a basic helix-loop-helix leucine zipper (bHLH-LZ) transcription factor activated by glucose metabolites. It forms heterodimers with MLX to bind carbohydrate response elements (ChoREs) in target gene promoters, driving the expression of enzymes involved in glycolysis (e.g., pyruvate kinase), lipogenesis (e.g., fatty acid synthase), and gluconeogenesis.

Primarily expressed in liver, adipose tissue, and pancreatic β-cells, MLXIPL plays a critical role in converting excess carbohydrates into storage lipids. Dysregulation of MLXIPL is linked to metabolic disorders, including obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD). Its activity is modulated by post-translational modifications (e.g., phosphorylation) and interactions with co-regulators like AMPK.

Antibodies targeting MLXIPL are essential tools for studying its expression, localization, and function in metabolic pathways. They enable detection via Western blotting, immunohistochemistry, and immunofluorescence, aiding research into metabolic syndrome, hepatic fibrosis, and cancer, where MLXIPL is often aberrantly expressed. Validated antibodies ensure specificity across species (human, mouse, rat), supporting both basic research and therapeutic development.